Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Change from baseline in total PANSS score to the end of the double-blind phase.
Assessment of global improvement in severity of illness; Evaluations of the benefits to quality of life; Assessment of the benefits to personal and social functioning. Incidence of adverse events throughout study.
18 Years and older (Adult, Older Adult)
March 12, 2004
June 8, 2011
† Study has passed its completion date and status has not been verified in more than two years.